Citation Impact
Citing Papers
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
2011
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
2011 Standout
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
2010
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI)
2012
A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)
2012
The views and practice of oncologists towards nutritional support in patients receiving chemotherapy
2006
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
2019
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
2014
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
2014
Gastric cancer
2016 Standout
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
2014
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
2018
Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer
2015
Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres
2010 Standout
CA 19-9 Velocity Predicts Disease-Free Survival and Overall Survival After Pancreatectomy of Curative Intent
2008
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
2011
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
2013
The Prevalence of Concern About Weight Loss and Change in Eating Habits in People with Advanced Cancer
2006
ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology
2006 Standout
Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials
2013
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
2010
Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
2013
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
2013
Symptoms tell it all: A systematic review of the value of symptom assessment to predict survival in advanced cancer patients
2012
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
2010
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
2010
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS)
2015
Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer
2010
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
2010
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Exercise-Induced Oxidative Stress: Cellular Mechanisms and Impact on Muscle Force Production
2008 Standout
Contribution of platelets to tumour metastasis
2011 Standout
Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study
2009
Pancreatic cancer
2020 Standout
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
2012
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
2013
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
2010
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
2009
Trial Watch: Monoclonal antibodies in cancer therapy
2012
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
2016
Carbohydrate antigen 19‐9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine‐containing chemotherapy
2012
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
2019
Redox regulation in anabolic and catabolic processes
2006
Randomized Prospective Phase II Study to Compare the Combination Chemotherapy Regimen Epirubicin, Cisplatin, and 5-Fluorouracil With Epirubicin, Cisplatin, and Capecitabine in Patients With Advanced or Metastatic Gastric Cancer
2011
A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer
2012
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
2012
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
2013
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Esophageal Cancer
2003 Standout
Definition and classification of cancer cachexia: an international consensus
2011 Standout
Chemotherapy for advanced gastric cancer
2010
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer
2002
Colorectal cancer
2013 Standout
Molecular Regulation of Muscle Cachexia: It May Be More Than the Proteasome
2002
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
2009
Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer
2009
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG
2017
Oesophageal carcinoma
2013 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial
2019
Circulating tumour cells in non-metastatic breast cancer: a prospective study
2012
Risk assessment for cancer-associated thrombosis: What is the best approach?
2012
Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases
2003
Incidence and predictors of venous thromboembolism (VTE) among ambulatory high‐risk cancer patients undergoing chemotherapy in the United States
2012
Guidelines for the management of oesophageal and gastric cancer
2011
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
2009
A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer
2013
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
2010
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
2008
Gastric cancer
2020 Standout
Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer
2010
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis
2010
Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90
2017
Pancreatic Cancer
2010 Standout
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial
2011
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Unmet needs and challenges in gastric cancer: The way forward
2014
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study
2013
Advanced gastric cancer: Current treatment landscape and future perspectives
2016
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
2006 Standout
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
2013
Gastric cancer: ESMO–ESSO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
2012
Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy
2008
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
2004 Standout
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
2014
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
2011
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)
2011
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
2015
Rechallenge with Platinum plus Fluoropyrimidine +/– Epirubicin in Patients with Oesophagogastric Cancer
2010
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
2008
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
2008 Standout
Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs. Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis (JCOG0106)
2013
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial
2015
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study
2015
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
2009
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
2017 Standout
S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study
2013
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
2012
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis
2011
The Calpain System
2003 Standout
Estimation of Cachexia among Cancer Patients Based on Four Definitions
2009
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
2014
Epidemiology of cancer-associated venous thrombosis
2013
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
2013
Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer
2013
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
2011
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
2008
Part 8: Post–Cardiac Arrest Care
2015 Standout
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
2018
Mismatch Repair Deficiency, Microsatellite Instability, and Survival
2017
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
2013 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
2014
Treatment of a Patient with Advanced Esophageal Cancer with a Combination of Mitomycin C and Capecitabine: Activation of the Thymidine Phosphorylase as Active Principle?
2003
CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
2012
Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data
2004
Global cancer statistics, 2012
2015 Standout
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
2015 Standout
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
2017
Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer
2002
Works of J. Oates being referenced
Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)
2012
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer
1997
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
2005
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
1998
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group
2009
Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
2010
Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer
2006
FcγRIIaandFcγRIIIaPolymorphisms and Cetuximab Benefit in the Microscopic Disease
2014